Comparing olanzapine to placebo for preventing nausea from chemotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of olanzapine compared to a placebo in preventing nausea and vomiting in patients undergoing moderately emetogenic chemotherapy. It is a randomized, phase 3 trial that includes patients receiving their first dose of chemotherapy agents such as oxaliplatin, irinotecan, or carboplatin. Participants will receive either olanzapine or a placebo in addition to standard antiemetic treatments to assess the difference in outcomes related to nausea and vomiting.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* histologically confirmed cancer patients who will be started on first dose of oxaliplatin, irinotecan or carboplatin
* age of \>18 years old

Exclusion Criteria:

* pregnancy or breast feeding
* has emetic episode within 24 hours
* gut obstruction
* uncontrolled brain metastasis
* allergy to or current use of olanzapine
* concomittant moderate or high emetogenic chemotherapy on day 2-5
* Total bilirubin \> 2 mg/dl or creatinine clearance \< 30 ml/min
* unable to swallow drug

Where it's running

• Faculty of Medicine Siriraj Hospital, Mahidol University
  Bangkok, Bangkok, Thailand Recruiting

Study contacts

• Study coordinator: Suthinee Ithimakin Ithimakin, MD
• Email: aesi105@yahoo.co.th
• Phone: 66898127440

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Fosaprepitant plus palonosetron with dexamethasone (± olanzapine) to prevent nausea from multi-day highly emetogenic chemotherapy

  This trial tests whether giving fosaprepitant and palonosetron with dexamethasone, with or without olanzapine, can prevent nausea and vomiting in adults starting multi-day highly emetogenic chemotherapy.

  Recruiting Phase 4 Shanghai 6th People's Hospital · Shanghai, Shanghai Municipality · NCT07482891

• Using Dolasetron to Prevent Nausea and Vomiting in Children with Leukemia

  This study is testing if dolasetron can help prevent nausea and vomiting in children with leukemia who are receiving chemotherapy.

  Recruiting Anhui Provincial Children's Hospital · Hefei, Anhui · NCT06756022

• Using guided imagery to reduce nausea and vomiting in children undergoing chemotherapy

  This study is testing if using guided imagery can help reduce nausea and vomiting in children aged 7 to 18 who are receiving chemotherapy.

  Recruiting Baskent University · Ankara, Ankara · NCT06120764

• Using Thalidomide to Reduce Nausea from Chemotherapy in Pancreatic Cancer

  This study is testing if thalidomide can help reduce nausea and improve the quality of life for people with pancreatic cancer who are receiving chemotherapy.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT06017284

• Using digital technology to manage chemotherapy-related nausea and vomiting in older adults

  This study is testing a digital program to help older adults manage nausea and vomiting while they go through chemotherapy to see if it improves their quality of life.

  Recruiting at 2 sites University of Central Florida · Miami, Florida and 1 other locations · NCT05838638

• HR20013 for preventing nausea and vomiting in cancer patients receiving chemotherapy

  This real-world study tests whether HR20013 helps prevent nausea and vomiting in adults with cancer who are getting chemotherapy.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT07874308

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.